NSE · SUNPHARMA.NS
Sun Pharmaceutical Industries Limited
₹1,822.90+₹61.90 (+3.52%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 10.82% below the high.
Loading market information…
NSE · ASTRAZEN.NS · INR
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 09:01 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
AstraZeneca Pharma India Limited’s quoted price sits in the lower half of its reported 52-week range, 35.52% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
AstraZeneca Pharma India Limited’s forward annual dividend is ₹36.00 per share, paid annual. The forward yield is 0.57% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow AstraZeneca Pharma India Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
AstraZeneca Pharma India Limited operates as a biopharmaceutical entity, engaged in the development, production, and global commercialization of pharmaceutical products, serving both the Indian domestic market and international clientele. The company offers an extensive range of medications, including treatments for cardiovascular conditions and diabetes, marketed under brands such as Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN. Its respiratory portfolio features products like Symbicort and FASENRA, while its oncology division provides various cancer therapies, including LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex. Furthermore, the firm extends its product line to encompass therapeutic solutions for renal, metabolic, and immunological disorders. Beyond its pharmaceutical offerings, AstraZeneca Pharma India Limited also provides clinical trial services. Established in 1979, the company is based in Bengaluru, India, and functions as a subsidiary of AstraZeneca Pharmaceuticals AB.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 09:01 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| ₹4.40B+118.53% vs estimate |
| Q2 2025 | Nov 13, 2024 | ₹15.37+197.87% vs estimate | ₹4.08B+132.6% vs estimate |
|---|
| Q1 2025 | Aug 8, 2024 | -₹4.72-156.94% vs estimate | ₹3.88B+92.34% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
₹1,822.90+₹61.90 (+3.52%)
Sun Pharmaceutical Industries Limited’s quoted price sits in the upper half of its reported 52-week range, 10.82% below the high.
₹4,606.10+₹26.10 (+0.57%)
Torrent Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 12.26% below the high.
₹1,355.00+₹10.00 (+0.74%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.23% below the high.
₹1,373.60+₹15.60 (+1.15%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 13.79% below the high.
₹2,009.80+₹19.90 (+1.0%)
Lupin Limited’s quoted price sits in the lower half of its reported 52-week range, 20.55% below the high.
₹2,315.10-₹23.90 (-1.02%)
Glenmark Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 8.77% below the high.
₹5,083.50+₹4.50 (+0.09%)
Alkem Laboratories Limited’s quoted price sits in the lower half of its reported 52-week range, 14.33% below the high.
₹3,538.60+₹78.90 (+2.28%)
Ajanta Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 6.78% below the high.
